This week… one of the oldest diabetes companies is looking ahead – Once part of BD, makers of needles and syringes, Embecta is now working on new technology like a patch pump. I’m talking to CEO Dev Kurdikar about moving the company forward, while still serving the patient community that relies on their established technology.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Please visit our Sponsors & Partners - they help make the show possible!
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
When the FDA cleared the 3 FreeStyle Libre 2 and FreeStyle Libre 3 (iCGM) system sensors for integration it meant a big leap forward to interoperability. For the first time in the US, insulin pumps can work with two different sensors.. Libre and Dexcom. This week, Stacey talks to Dr. Jordan Pinsker, medical director for Tandem Diabetes Care, about the upcoming Libre integration, the Mobi pump that's in front of the FDA right now, and much more. Dr. Pinsker has extensive experience with automated systems – he’s been there since close to the beginning and we talk about the long process to bring them to market, how they’re changing lives and what is still yet to come.
More about the Libre approval: https://beyondtype1.org/freestyle-libre-aid-clearance/
More about Dr. Pinsker: https://www.tandemdiabetes.com/providers/bio/jordan-pinsker
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Please visit our Sponsors & Partners - they help make the show possible!
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Last fall, Tzield was approved to delay type 1 diabetes in people predicted to develop it. This week, I’m talking one of the first families to use what used to be called Teplizumab for their son, as a regular patient, outside the clinical trials. How exactly does this all work? Who’s eligible and how do you cover the enormous financial cost?
Amanda Troutman talks about why they went through this process with her son, William. Their whole family was tested for the genetic markers after their daughter, Jenna, was diagnosed in 2020.
As always, this podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Our previous episodes on Tzield: https://diabetes-connections.com/?s=teplizumab
More about the Troutman family: https://www.vcuhealth.org/news/north-carolina-teen-among-first-in-us-to-receive-new-diabetes-drug
Please visit our Sponsors & Partners - they help make the show possible!
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Dexcom’s G7 has been available in the US for less than two weeks, but the company continues to look ahead. Part of the future? Their Type Zero group – which created Tandem’s Control IQ – is working on a truly closed loop system.
Chief Operating Officer Jake Leach spoke to Stacey from the recent ATTD Conference. Of course we also asked a bunch of your G7 questions and had a more in-depth discussion about CGM monitoring for people without diabetes.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Please visit our Sponsors & Partners - they help make the show possible!
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Infusion sets have always seems like the weak link of pumping for us. What good is the best algorithm and state of the art pump and CGM if the way it all attaches to the body is no good? New information shows infusion failures happen more than you may think. John Wilcox's company, DiaTech Diabetes, has an infusion set failure detection system. He’s going to explains what that is, how it works and what you can do with the sets you have right now to make them more effective
More here: https://diatechdiabetes.com/
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Please visit our Sponsors & Partners - they help make the show possible!
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
Tandem Diabetes has made some big moves recently, acquiring two new companies – one makes infusion sets, the other a patch pump called Sigi, and their tiny Mobi pump is in front of the FDA right now. We’re finding out how it may all come together from Tandem’s EVP and Chief Strategy Office Elizabeth Gasser. We talk about how these acquisitions have changed Tandem’s road map – you may remember they released that look into the future last year – G7 integration, software updates and a lot more.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
2022 Episode with Tandem, includes links to the original 5-year road map
Please visit our Sponsors & Partners - they help make the show possible!
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
The US FDA has approved Tidepool Loop, an app designed to automate insulin dosing. Born out the do-it-yourself, "we are not waiting" movement, it has designs and features not in the first wave of commercial automated systems like Omnipod 5 and Tandem’s Control IQ. CEO Howard Look talks to Stacey about what was approved here and what Tidepool Loop is all about.
If you’ve followed this story closely, you’re going to be surprised to learn about a few changes that have happened along the road to approval.. and to learn the questions that Tidepool will have to answer next.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Learn more about Tidepool: https://www.tidepool.org/
Our previous episodes with Howard Look:
Please visit our Sponsors & Partners - they help make the show possible!
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: info@diabetes-connections.com
We've got new information about Dexcom’s G7 launch and much more. CEO Kevin Sayer says it’ll be available in the US before the end of March. Sayer joins us from the J.P. Morgan Healthcare Conference in San Francisco. He talks about Dexcom’s pump partners, when the FDA will let them put in features they already have in Europe but not here, and answers a lot of your questions.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Stacey mentioned this link during the episode: www.dexcom.com/g6-medicare
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
Happy new year! What will 2023 bring for diabetes technology? We bring our best guesses to the table and we take a look back at what we said would happen last year. Stacey is joined by Chris Wilson on a Twitter Spaces Chat and you'll also hear from Mike Hoskins for a look back to 2022.
Mike is currently an editor at Healthline and formerly the managing editor at DiabetesMine. Chris Wilson, is a longtime advocate and information junkie who just marked 25 years with type 1. Chris will tell you that for much of his time with diabetes he didn’t have insurance and didn’t use a lot of the more advanced tech.. and now he really follows it all very closely, takes part in clinical trials and is designing his own pretty incredibly sounding DIY closed loop features.
None of the three have financial stakes in these companies, past some stocks that may be buried in mutual funds – we don’t’ own individual stakes in these companies. And their information is based on whatever is publicly available.
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!
This week.. after a year of deliberations, the US FDA approves the newest product from Dexcom, the G7. This is a much smaller device, with all-in-one sensor and transmitter, shorter warm up time and many more new features.
Stacey talks with Dexcom’s Chief Operating Officer Jake Leach. They do a lighting round of questions to learn more about what was – and was NOT – approved here. It’s not exactly what’s already on the market in Europe.. and we look ahead to what’s next.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Previous episodes on the G7: https://diabetes-connections.com/?s=g7
Watch the interview on our YouTube channel: https://www.youtube.com/@diabetesconnections
Check out Stacey's book: The World's Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners - they help make the show possible!